Last reviewed · How we verify
Botulinum toxin type A injection [HG-102]
Botulinum toxin type A injection [HG-102] is a Small molecule drug developed by Hugel. It is currently in Phase 1 development. Also known as: HG-102.
At a glance
| Generic name | Botulinum toxin type A injection [HG-102] |
|---|---|
| Also known as | HG-102 |
| Sponsor | Hugel |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Botulinum toxin type A injection [HG-102] CI brief — competitive landscape report
- Botulinum toxin type A injection [HG-102] updates RSS · CI watch RSS
- Hugel portfolio CI
Frequently asked questions about Botulinum toxin type A injection [HG-102]
What is Botulinum toxin type A injection [HG-102]?
Botulinum toxin type A injection [HG-102] is a Small molecule drug developed by Hugel.
Who makes Botulinum toxin type A injection [HG-102]?
Botulinum toxin type A injection [HG-102] is developed by Hugel (see full Hugel pipeline at /company/hugel).
Is Botulinum toxin type A injection [HG-102] also known as anything else?
Botulinum toxin type A injection [HG-102] is also known as HG-102.
What development phase is Botulinum toxin type A injection [HG-102] in?
Botulinum toxin type A injection [HG-102] is in Phase 1.
Related
- Manufacturer: Hugel — full pipeline
- Also known as: HG-102
- Compare: Botulinum toxin type A injection [HG-102] vs similar drugs
- Pricing: Botulinum toxin type A injection [HG-102] cost, discount & access